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Guelphs” and “The Ghibellines” (factions supporting the Church
and the Holy Roman Empire, respectively) characterized a particu-
larly intense aspect of the internal politics in the city-states of cen-
tral and northern Italy, particularly in Tuscany. The Guelph-
Ghibelline conflict, which was described also in Dante's Divina
Comedia, gave way to an especially ferocious and painful civil war
lasted for decades, and ending without a real winner [1].
In 2000, a preliminary investigation on remifentanil as a sys-
temic drug for obstetric analgesia concluded that remifentanil
was “unsuitable during labour” [2]. Months later (2001) a prospec-
tive study on the same topic stated that it had the properties of
an “ideal systemic analgesic for use during labour” [3]. Since then
something like 160 articles evaluating the use of intravenous remi-
fentanil for labour analgesia, resulted in mixed findings regarding
its safety and efficacy in attenuating labour pain if compared with
other opioids or neuraxial techniques. Some strong statements
were in favor of remifentanil “… it is an important advance in the ob-
stetric anesthesia armamentarium for parturients who do not want
neuraxial analgesia” [4]. While some others were against it: “…
routine use in labour must be discouraged … must we press on until
a young mother dies?” [5]. This scientific epistolary conflict (no
holds barred) sounds like the “Guelphs vs Ghibellines” but among
two obstetric anesthesiologists “factions”, and it has been now last-
ing for two decades: on one hand thosewho strongly supported the
technique and on the other, with just as much commitment, the
opponents.
The pain associated with labour is highly personal and varies
greatly among individual, but most of women do experience any-
thing but modest pain during labour, resulting in negative physical,
emotional and psychological effects [6].
In the December issue of Trends in Anaesthesia and Critical Care
[7], Andrea Melber and Alex Sia, explore efficacy, safety and risks of
remifentanil Patient-Controlled intravenous Analgesia (PCA) for la-
bour in relation to the other better established pharmacological
methods. We want to thank the authors to point out some
worthy-of-support statements and to provide us with the opportu-
nity to make a point.
Firstly: “the efficacy of remifentanil PCA may be found between
neuraxial analgesia and other commonly used pharmacological tech-
niques.” Based on current evidence remifentanil PCA provides bet-
ter analgesic quality than pethidine and nitrous oxide, the two
“pharmacological competitors”. However, remifentanil remains
significantly less effective when compared to neuraxial analgesia.
Remifentanil appears more effective during the first stage
compared to the second stage of labour, when somatic pain, more
resistant to opioids, occurs. Furthermore tachyphylaxis,
remifentanil-induced hyperalgesia, or difficulty to synchronize
the peak of remifentanil effect with the peaks of contractions mighthttps://doi.org/10.1016/j.tacc.2018.04.011
2210-8440/© 2018 Elsevier Ltd. All rights reserved.further explain its reduced efficacy [8,9].
Secondly: “… the serious concern for maternal safety is justified.
Thorough and continuous observation during the application of remi-
fentanil PCA is of utmost importance.” The fast onset of action and
rapid clearance are properties that should make remifentanil an
ideal drug for PCA use, but its potency may cause serious side ef-
fects [10]. Literature reported cases of remifentanil PCA associated
with nausea and vomiting, arterial hypotension, muscle stiffness,
bradycardia, hyperalgesia but especially respiratory depression
(up to 26% of treated patients) [11]. Case reports of more serious
events, such as cardiac arrest (presumably arising from induced
respiratory arrest) have been described [12].
The variations in the bolus dose required for effective analgesia
(20e60 mcg, 1e3min of lockout) and the difficulties in identifying
the optimal administration of remifentanil during labour (PCA,
continuous infusion or a combination of PCA and a continuous infu-
sion) may have a different impact on patient safety [13]. Oxygen
supplementation and continuous monitoring of vital signs (blood
pressure, heart rate, respiratory rate, SpO2, EtCO2, level of con-
sciousness) must be ensured. One-to-one midwifery/nursing care,
the availability of a physician experienced in neonatal resuscitation
and a supervising anesthesiologist, with experience regarding the
use of remifentanil, are important to ensure that this method re-
tains its credit for obstetric analgesia. Unrealistic expectations in
terms of analgesia by patients and staff increase the risk for an
adverse event [14].
From the fetal-neonatal side, remifentanil has less side effects
than other parenteral opioids. Should reduced fetal heart rate vari-
ability be observed, the reported need for neonatal resuscitation is
low [8].
Thirdly: “In the use of Remifentanil PCA … new technology … will
hopefully improve this aspect of care for the parturient”. In addition to
one-to-one midwifery/nursing surveillance, with the aim of
increasing the safety of remifentanil analgesia, a promising novel
feedback system, integrating a vital signs-controlled and patient-
assisted intravenous remifentanil analgesia (VPIA) has been devel-
oped [15]. The system automatically increases or decreases the
bolus doses based on parturient's requests of remifentanil and
stops further remifentanil administration in the presence of
maternal hypoxia, thanks to integrated real-time continuous
maternal data obtained from pulse oximetry and heart rate values.
An implementation of the systemwith capnography and fetal heart
rate monitoring has been recommended [16]. An algorithm based
on a time series of painful contractions during labour, which can
predict the future contractions with sufficient precision, optimizing
remifentanil bolus application and so improving the efficacy of PCA
during first-stage labour, has also been developed [17].
Two final considerations. Remifentanil PCA technique will
become safer and more effective than it is today, however a strong
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rapidly convert analgesia to surgical anesthesia for unscheduled ce-
sarean delivery. Especially in complicated parturients (e.g.
morbidly obese) the early placement of an epidural catheter for la-
bour analgesia can avoid the associated risks of general anesthesia
when operative delivery/non scheduled cesarean section is
required [18]. Based on current scientific evidence, neuraxial anal-
gesia seems to be the only “routine” viable option and probably the
actual gold standard for labour analgesia, which someway results in
a painful search of a painless labour.
Women requesting pain relief for labour who have contraindica-
tions for an epidural block (impaired coagulation due to prophylac-
tic anticoagulants, or pre-existing blood clotting abnormality or
platelet dysfunction) or when central neuraxial analgesia may be
technically impossible to perform, could benefit from intravenous
remifentanil analgesia. However significant availability of medical
staff and monitoring devices, and large-scale studies are needed
before remifentanil can be safely recommended as a “standard”
in this context.
Until this time comes, our duty is to pursue patients' safety and
satisfaction, and to provide, as from excellent research fromMelber
and Coworkers [7], the search of the perfect painless labour. A search
which is part of our nature, as from same Dante Alighieri's words:
“Considerate la vostra semenza: fatti non foste a viver come bruti,
ma per seguir virtute e conoscenza” [“Consider ye the seed from
which ye sprang: Ye were not made to live like unto brutes, But
for pursuit of virtue and of knowledge”] [19].References
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